




The relative strengths and weaknesses of PUMA Biotechnology INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PUMA Biotechnology INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 160% points. The greatest weakness of PUMA Biotechnology INC is the variable Other Revenues, reducing the Economic Capital Ratio by 21% points.

The company's Economic Capital Ratio, given in the ranking table, is 327%, being 107% points above the market average of 220%.

Input Variable	Value in 1000 USD
Assets, Current	148,972
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	21,701
Liabilities, Non-Current	0
Other Assets	1,248
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	1,089
Other Net Income	98
Other Revenues	0
Property and Equipment	1,479
Research and Development	49,636
Selling, General and Administrative Expense	24,814

Output Variable	Value in 1000 USD
Assets	151,699
Liabilities	22,790
Expenses	74,450
Revenues	0
Stockholders Equity	128,909
Net Income	-74,352
Comprehensive Net Income	-74,352
BaseVar	124,518
ECR before LimitedLiability	237%
Economic Capital Ratio	327%